68 CHAPTER 4 Table 1 | Summary table of preventive interventional trials in individuals at risk of developing rheumatoid arthritis (continued) Trial name Inclusion criteria Number of patients (treatment vs placebo) Intervention Time of follow-up Primary outcome Secondary outcome Results Reference APIPPRA study - CSA - ACPA and RF positivity or high ACPA serum levels 206 patients 125 mg weekly abatacept for 1 year - 52 weeks - 2 years - Feasibility, efficacy, and acceptability of treatment - Characterization of immune response - Time to development of clinically apparent synovitis in ≥3 joints or RA per ACR/EULAR 2010 criteria - RA progression - Disease activity - Percentage of patients requiring DMARDs - Adverse events - Patients’ perception - Study concluded. Results expected in 2022 [62]
RkJQdWJsaXNoZXIy MTk4NDMw